Centro Médico Teknon
Centro Médico Teknon
Hiszpania, Barcelona
Jorge Moises Sandrus
36 lat doświadczenia
akredytacje :
Akredytacje :
| Turcja | Austria | Hiszpania | |
| Terapia objawowa | od $300 | od $700 | od $800 |
Dr Batista zapoczątkował operacje laserowe w Barcelonie i przeprowadził ponad 1100 zabiegów urologicznych. Założył i kieruje oddziałem Uroclínica w Centro Médico Teknon.
Wiodący specjalista w dziedzinie andrologii i urologii z ponad 15-letnim doświadczeniem — dr Torremade kieruje Oddziałem Andrologii w Centrum Medycznym Teknon.
Dr Navarro Vilches specjalizuje się w zaawansowanej chirurgii nerek i kieruje Oddziałem Urologii w Quirónsalud Marbella.
Dr. Antonio Allona is Director of the Urology Unit at Hospital Ruber Internacional (Madrid) since 1993. He has more than 40 years of experience in prostate cancer, reconstructive urology, and andrology. He is known for complex urological surgery and advanced cancer treatments.
Career: Head of Urology and Andrology at Ruber Internacional. Senior Urologist at Hospital Universitario Ramón y Cajal (1981–2010). Specialist at Centro Médico Teknon.
Credentials: MD, University of Granada (1977), Special Degree Award. PhD, University of Alcalá de Henares, cum laude (thesis on detubularised ileal reservoir). FEBU Fellow (1992). Foreign Medical Examination certification (1980).
Contributions: Member of the National Commission of Urology (1986–2004). General Secretary of the AEU for eight years. Held board roles in international societies. Contributed to advances in bladder reconstruction and functional urology. Member of the AEU, Spanish Association of Andrology, EAU, AUA, SIU, and the American Confederation of Urology.
Top hospitals in Spain for polycystic kidney disease (PKD) treatment include JCI-accredited facilities like Centro Médico Teknon and Hospital Quiron Barcelona. These centers provide expert urological consultations. They manage symptoms and complications of PKD using robotized surgeries and advanced imaging like MRI.
Bookimed Expert Insight: Choosing a large hospital network like HM Hospitales or Quirónsalud provides a significant safety net. These networks, such as Hospital HM Nou Delfos or Quironsalud Madrid, serve over 400,000 patients yearly. This high volume ensures that specialists have extensive experience with rare PKD complications. Patients also gain access to clinical trials for neurodegenerative research through these larger institutions.
Patient Consensus: Patients note it is important to choose hospitals that offer personalized care and international services. They appreciate clinics that provide airport transfers and nearby hotel accommodations to make the treatment process smoother.
Expert nephrologists in Spain treat polycystic kidney disease using advanced molecular diagnostics and robotic surgery. Dr. Roser Torra and Dr. Jorge Moises Sandrus are leading specialists in Barcelona. Patients access multidisciplinary care at JCI-accredited centers like Centro Medico Teknon and Hospital Quiron Barcelona.
Bookimed Expert Insight: Barcelona has become a primary hub for hereditary kidney care due to massive patient volumes. Centro Medico Teknon alone manages 10,000 patients annually. This high concentration of cases allows specialists to refine diagnostic protocols for rare genetic variations. Doctors here often coordinate between 50 different departments to manage multi-organ PKD symptoms.
Patient Consensus: Patients note the importance of choosing centers with international departments for smooth coordination. Many highlight that personalized treatment plans in Barcelona often combine genetic counseling with long-term monitoring.
Tolvaptan is available in Spain as a standard treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The drug is used in major hospitals to slow cyst growth. Eligible adults must show rapid progression and satisfy specific kidney function criteria. European Medicines Agency protocols require local monthly liver monitoring.
Bookimed Expert Insight: Spain ranks third globally on Bookimed for medical travel, reflecting a highly regulated healthcare system where innovative drugs like Tolvaptan are integrated into clinical networks. While large public centers manage many cases, private facilities like those in the HM Hospitales network offer streamlined access to specialists like Dr. Javier Romero Otero. This ensures that international patients can receive advanced symptomatic treatment in JCI-accredited environments that handle over 400,000 patients annually.
Patient Consensus: Patients note that while the national health system covers the drug, regional approvals can take around 3 months to finalize. Those using the medication emphasize that initial side effects like extreme thirst usually become more manageable after several weeks.
Spanish clinics treat polycystic kidney disease through symptomatic management and advanced surgical interventions. Specialists focus on slowing cyst growth with targeted drug therapies like Tolvaptan. High-volume centers in Barcelona and Madrid integrate minimally invasive urology and robotic systems to manage complications and preserve renal function effectively.
Bookimed Expert Insight: Spanish healthcare excellence is driven by massive patient volumes and specialized expertise. Hospital HM Nou Delfos and Centro Médico Teknon each treat over 10,000 patients annually. Doctors like Dr. Jose Emilio Batista Miranda bring over 35 years of experience to complex cases. This high volume across JCI-accredited facilities ensures refined clinical protocols and reliable outcomes for chronic renal management.
Patient Consensus: Patients value the speed of donor matching in Spain compared to other countries. Many note that conservative lifestyle changes and blood pressure control are prioritized before considering more invasive surgical options.